Licensees. Any license of any Optioned Antibody and any sublicense of the rights granted under Section 3.2(b)(ii) (License) shall be made solely pursuant to agreements that are consistent with all relevant terms and conditions of this Agreement and to Licensees who explicitly agree in writing to comply with all applicable terms, including Section 9.3 (
Appears in 2 contracts
Sources: Sublicense Agreement (CASI Pharmaceuticals, Inc.), License Agreement (CASI Pharmaceuticals, Inc.)
Licensees. Any license of any Optioned Antibody and any sublicense of the rights granted under Section 3.2(b)(ii3.2(b) (LicenseDevelopment and Commercialization License and Assignment) shall be made solely pursuant to agreements (“Sublicense Agreements”) that are consistent with all relevant terms and conditions of this Agreement and to Licensees who explicitly agree in writing to comply with all applicable termsterms of this Agreement, including Section 9.3 (Commitments Regarding Program-Benefited Antibodies) hereof. [***].
Appears in 2 contracts
Sources: Collaboration Agreement (Leap Therapeutics, Inc.), Collaboration Agreement (Leap Therapeutics, Inc.)
Licensees. Any license of any Optioned Antibody and any sublicense of the rights granted under Section 3.2(b)(ii3.2(b) (LicenseDevelopment and Commercialization License and Assignment) shall be made solely pursuant to agreements (collectively, “Licensee Agreements”) that are consistent with all relevant terms and conditions of this Agreement and to Licensees who explicitly agree in writing to comply with all applicable termsterms of this Agreement, including Section 9.3 9.4 (
Appears in 1 contract